Bone marrow clues may predict chemo success in AML
NCT ID NCT07587944
First seen May 20, 2026 · Last updated Jun 20, 2026 · Updated 7 times
Summary
This study looks at how substances in the bone marrow, like IL-6 and leptin, influence chemotherapy resistance in acute myeloid leukemia (AML). Researchers will enroll 405 newly diagnosed AML patients and 81 healthy controls to measure these factors and link them to treatment outcomes. The goal is to find better ways to predict prognosis and identify new targets for therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fujian Medical University Union Hospital
RECRUITINGFuzhou, Fujian, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could help doctors better predict which AML patients will respond to chemotherapy and point toward new treatment targets.
What could go wrong
This is an observational study, not a treatment trial. It may not lead directly to new therapies, and findings may not apply to all AML patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.